PDC*line Pharma

Tomorrow’s the day! 🚀 We’re excited to share that our CEO Eric Halioua will be speaking at Advanced Therapies UK 2025, where industry leaders will gather for two days of insightful discussions, networking, and innovation. There’s still time to join us in London—don’t miss out! #AdvancedTherapies #Biotech #Networking #Innovation https://lnkd.in/eu7s2sb3

👉 New Publication Alert! We are excited to share our latest research, conducted in collaboration with the Etablissement Français Du Sang - French Blood Bank (EFS), now published in Hepatology Communications! This study highlights the potential of PDC*line, our allogeneic plasmatycoid dendritic cell platform, in identifying novel immunogenic HLA-A*02:01 epitopes associated with hepatocellular carcinoma (HCC) for immunotherapy development. 🔬 Key Findings: ✅ Identified 16 ectopically expressed genes as potential targets in HCC. ✅ Validated three highly immunogenic epitopes capable of triggering a strong CD8+ T-cell response: - MAGE-A3 (FLWGPRALV) - AFP (FMNKFIYEI) - LRRC46 (KMFHTLDEL) ✅ These  tumor-specific epitopes induced robust T-cell activation, degranulation, and IFN-γ secretion, supporting their potential use in novel cancer vaccines and immunotherapies. 🌟 Why it Matters: HCC remains one of the most challenging cancers to treat, with limited response to conventional therapies. Our findings contribute to the development of immunotherapies, leveraging epitope-specific T-cell responses to improve clinical outcomes.   📖 Read the full article here: 🔗 https://lnkd.in/eHk3TNJ4   A big thank you to our collaborators at EFS and the PDC*line Pharma team for making this research possible! Let’s keep pushing the boundaries of cancer immunotherapy together!   #Immunotherapy #Oncology #HCC #CancerResearch #DendriticCellTherapy #TCellTherapy #Innovation #Collaboration

We are thrilled to welcome Eric Halioua President & CEO of PDC*line Pharma to Our 𝟐𝟐𝐧𝐝 𝐁𝐢𝐨𝐏𝐡𝐚𝐫𝐦𝐚 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐍𝐞𝐱𝐮𝐬! Join us as he presents groundbreaking insights into a new class of antigen-specific cancer active immunotherapies based on the potent PDC*line technology. This is a must-attend session for anyone passionate about the future of oncology and immunotherapy! 📅29th & 30th April, 2025 📍 Holiday Inn Brussels, Belgium Let’s shape the future of cancer treatment together! Register Now : https://lnkd.in/dSz-gc7c #NexusConference #Biopharma #DrugDiscovery #CancerResearch #Immunotherapy #Oncology #Biotech #MedicalInnovation #HealthcareTech #CancerTreatment #PrecisionMedicine #PharmaTech #FutureOfMedicine #LifeSciences

A panel discussion you don't want to miss at the Advanced Therapies event in March! 👇 Join us for the Opening Panel Discussion on "Tackling the Challenges of #Immunotherapy" featuring our CEO. Panelists include: Ajan Reginald, CEO, Roquefort Therapeutics plc (Chair) Eric Halioua, President & CEO, PDC*line Pharma SA Bahareh A., Lead Pharmacist for ATMPs, Manchester University NHS Foundation Trust James Jones, Honorary Consultant in Medical Oncology, University of Cambridge Stephen Sullivan, PhD, MBA, FRSM, Director, Lindville Bio Why attend? Hear from leading experts as they address key challenges and explore innovative solutions shaping the future of immunotherapy clinical trials. Secure your spot now: 👉 https://lnkd.in/ehXpgMiB #adtherapies25 #advancedtherapies #clinicaltrials

We are delighted to share that BioProcess International, a leading global platform for the bioprocessing industry, has featured an exclusive interview with our CEO, Eric Halioua. In this insightful piece, Eric takes us through PDC*line Pharma’s inspiring journey—from its founding to its latest breakthroughs in cancer immunotherapy. He also discusses the driving force behind our innovative platform, the resilience needed to navigate the biotech landscape, and the power of global partnerships in accelerating our success. 📖 Read the full article below : #Biotech #CancerImmunotherapy #Innovation #Leadership #Partnerships #BioProcessInternational

A heartfelt thank you to everyone who participated in PDC*line Pharma 's executive roundtable discussion at this year’s WuXi Global Forum in San Francisco during JP Morgan Week!* It was a pleasure exchanging ideas and insights with such a forward-thinking community. For those who couldn’t join us in person, you can relive the experience through the recap video below or on the digital content platform. #WuXiGlobalForum

I’m thrilled to be attending the J.P. Morgan Conference in San Francisco from Sunday to Wednesday evening. This event provides an incredible opportunity to engage with key players in the pharmaceutical industry, investors, and explore new horizons for PDC*line Pharma. 🚀 If you’re attending as well and would like to connect, feel free to reach out or meet me at the conference. Looking forward to dynamic discussions in this hub of innovation!

We are thrilled to be hosting an Executive Roundtable at WuXi AppTec’s #WuXiGlobalForum during #JPM2025! This event provides a great platform to share insights about PDCline Pharma’s cutting-edge cancer vaccine platform, including **PDC*lung**—our innovative cancer vaccine designed to treat metastatic NSCLC (non-small cell lung cancer) patients in combination with Pembrolizumab. Our CEO Eric Halioua will discuss about opportunities of innovative cancer vaccines and engage with industry leaders on shaping the future of oncology treatments. Let’s connect and exchange ideas! Learn more about the event here: https://lnkd.in/e36tbuAt

🎄 Happy Holidays from PDC*line Pharma! 🎄 As the holiday season approaches, we wish you and your loved ones moments filled with sweetness and joy. Here's to a Healthy, Hopeful, and Prosperous 2025 for all! The PDC*line Pharma Team

We are pleased to share an article recently published in BIOTECHFINANCES titled: "UN PAS DE PLUS POUR PDCLINE PHARMA." The article features an interview with our CEO, Eric Halioua, and highlights the latest clinical results from our Phase I/II trial with PDC*lung01. It also outlines the future milestones we aim to achieve as a company. 📢 In this exclusive interview, Eric Halioua discusses the vision behind PDC*line Pharma and the potential impact of our innovative approach on cancer treatments.